Brussels, Belgium: 14 April 2026 – Kaneka Ubiquinol, the sole global innovative manufacturer and pioneer of Ubiquinol, has announced its MTick certification, helping women to search, source and shop for menopause-friendly products with choice and confidence.
This marks a significant milestone in Kaneka Ubiquinol's commitment to advancing ongoing science and innovation in mitochondrial health support in the women’s health category.
Growing interest in cellular energy and mitochondrial health is reshaping nutraceutical innovation in women’s health, positioning Kaneka Ubiquinol as a foundational ingredient for brands developing evidence-driven formulations, particularly across preconception, menopause, healthy ageing and beauty from within.
The globally recognised milestone certification will be showcased at Kaneka Ubiquinol’s stand (3B102) at Vitafoods Europe 2026 (5–7 May), together with Kaneka Ubiquinol’s inaugural Mitochondrial Health Category Sponsor, reinforcing its role as a trusted innovation partner to its customers, at the forefront of evidence-based ingredient development in mitochondrial health with a core focus on women’s health.
Marking the announcement, Filip Van hulle, General Manager, Kaneka Ubiquinol Europe, said: “Achieving MTick certification represents an important step in our commitment to supporting women through all life stages with integrity, transparency and science-led innovation.”
“We are proud to integrate this certification into our broader leadership in mitochondrial health, ensuring innovation is aligned with the evolving needs of consumers, healthcare professionals and brand partners.”
The new certification comes at a pivotal time, with an estimated 1.2 billion women worldwide expected to be experiencing menopause by 2030 and approximately 47 million women entering this life stage each year.
As global focus on women’s health intensifies, demand is increasing for solutions grounded in cellular health. Mitochondria, often referred to as the body’s cellular batteries, generate approximately 90% of the body’s cellular energy, positioning mitochondrial function as a foundational component of overall wellbeing and long-term vitality.
Ubiquinol, the bioactive form of coenzyme Q10 (CoQ10), plays an essential role in cellular energy production and antioxidant protection within this system. Evidence shows that the decline in naturally occurring endogenous occurs from age of 20+. As natural Ubiquinol levels decline, mitochondrial energy may also decrease, by up to 30% at menopause.
“We are so proud that Kaneka Ubiquinol joins 120+ brands in the GenM collective, committed to empowering women through choice and trust – to understand, support and serve those in menopause better”, said Heather Jackson, CEO & GenM Founder.
“With 48 signs of menopause, this stage of life can impact every aspect of a woman’s life – and rather than overwhelming her, through the MTick she can be signposted to trusted products that can make the experience of menopause better today than yesterday”, Jackson added.
“It is these small changes that can make a huge difference to a woman’s lived experience of menopause. United by the MTick, Kaneka Ubiquinol, and GenM are delivering trust, choice and visibility to menopause, truly transforming the menopause shopping experience and driving the growth of a purposeful new retail category.”
At Vitafoods Europe 2026, Kaneka Ubiquinol will further reinforce its stature in the women’s health category through the Kaneka Mitochondrial Innovation Forum, a dedicated on-stand education platform at the Kaneka Ubiquinol Pavilion that will bring together leading global experts to explore the expanding role of mitochondrial science while also equipping brands with the science, technical expertise and commercial insight required to lead in the mitochondrial health category.
Kaneka Ubiquinol demonstrates flexibility in formulation and high stability across multiple delivery formats, including softgels, tablets, capsules, gummies, liquids and is supported by Kaneka’s technical expertise in stability testing, dosage optimisation, regulatory guidance and go-to-market strategy.
Industry partners, healthcare professionals and media are invited to attend the Kaneka Mitochondrial Innovation Forum at Vitafoods Europe from 5–7 May 2026 at Stand 3B102 to learn more. Register now.